NCT00945555已完成不适用
Multi-Center, Non-Interventional, Observational Study To Evaluate The Antibacterial Therapeutical Options In Febrile Neutropenia Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 264
- 试验地点
- 1
- 主要终点
- Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring Febrile Neutropenia (FEN) in Their Therapeutical Approach: Empirical
研究概览
简要总结
The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are 18 years old and above.
- •Patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy.
- •Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm^3) or below 1000 cells/mm^3 with an expectancy to rapidly decrease below 500 cells/mm^
- •Patients with a body temperature more than or equal to (≥)38.3 degrees Celsius (101 degrees Fahrenheit) on single oral measurement or detected ≥38.0 degrees Celsius for at least an hour and thus started on antibacterial treatment will be included in the trial.
排除标准
- •Patients who are pregnant or considering pregnancy.
研究组 & 干预措施
All participants
Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
干预措施: Antibacterial agent for the treatment of febrile neutropenia (Drug)
结局指标
主要结局
Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring Febrile Neutropenia (FEN) in Their Therapeutical Approach: Empirical
时间窗: Baseline
Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring FEN in Their Therapeutical Approach: Targeted
时间窗: Baseline
次要结局
- Mean Neutrophil Count(Baseline, Day 4, Day 7 on Average (till the End of Treatment))
- Percentage of Participants in Whom New Infection Was Determined on Day 4(Day 4)
- Percentage Survivors(Day 7 on Average (till the End of Treatment))
- Percentage of Participants Who Had a Treatment Modification(Day 4, Day 7 on Average (till the End of Treatment))
- Mean Body Temperature(Baseline, Day 4, Day 7 on Average (till the End of Treatment))
- Percentage of Participants in Whom New Infection Was Determined at End of Treatment(Day 7 on Average (till the End of Treatment))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life PracticeColitis, UlcerativeInflammatory Bowel DiseasesCrohn DiseaseNCT03532932Takeda1,990
已完成
3 期
Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)Urinary Tract InfectionNCT01478620Bionorica SE125
已完成
4 期
Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture.FungemiaSepsisBacteremiaNCT01450358Instituto do Coracao200
尚未招募
Unknown
Study of use of drugs used to treat bacterial infections and measuring vancomycin drug levelsCTRI/2024/04/065210I
终止
3 期
CleanUP IPF for the Pulmonary Trials CooperativeIdiopathic Pulmonary FibrosisNCT02759120Weill Medical College of Cornell University513